Levels of CD105+ cells increase and cell proliferation decreases during S-phase arrest of amniotic fluid cells in long-term culture

Abstract

The present study aimed to improve the characterization of amniotic fluid cells (AFCs) in order to optimize their use in chromosomal prenatal diagnosis and as seed or stem cells for tissue engineering. The AFCs used in the current study were obtained from three females in their second trimester of pregnancy. The cells were cultured independently and characterized by cell morphology, cell markers, cell cycle distribution and chromosome Giemsa banding in an early- and late-passage. The AFCs remained homogeneous in culture and expressed mesenchymal markers, but not endothelial markers along the culture process. In addition, compared with the early-passage cells, the late-passage cells exhibit an increase in CD105 expression, a decrease in cell division and a delay in the cell cycle, and a number of cells underwent cell cycle arrest. However, the cells retained a normal karyotype. Therefore, the current study characterized AFCs in a clinical culture and confirmed that AFCs are mesenchymal precursors. The results obtained may be useful for the application of AFCs in prenatal diagnosis.

Translating amniotic fluid-derived stem cells for transplantation in stroke

“…Additionally, other studies have shown the ability of AFMSCs to modulate the immune system, leading to restriction of T lymphocyte proliferation [8]. Moreover, increased CD105+ levels were found in the late-passage of the cell culture in contrast to the early-passage ASFC culture [9]. This provides evidence of AFSCs role as a mesenchymal precursor, in that the prevalence of CD105 and the longterm culture conditions permit mesenchymal cell growth [9].…”

“…Moreover, increased CD105+ levels were found in the late-passage of the cell culture in contrast to the early-passage ASFC culture [9]. This provides evidence of AFSCs role as a mesenchymal precursor, in that the prevalence of CD105 and the longterm culture conditions permit mesenchymal cell growth [9]. A recent in vitro investigation determined the gestational age (i.e., those derived from first-, second-to thirdtrimester) that influence AFSCs' function in regulating the proliferation of lymphocytes [10].…”

Quantifying Proliferative and Surface Marker Heterogeneity in Colony Founding Connective Tissue Progenitors and Their Progeny Using Time‐Lapse Microscopy

“…Their progeny do not conform to the positive cell marker criteria set by International Society of Cell Therapy for MSCs. Previous publications show variation in CD105 in early culture and an increase in CD105 expression with more time in culture (Anderson, Carrillo‐Gálvez, García‐Pérez, Cobo, & Martín, ; Pittenger et al, ; Wang et al, ). It is possible that the progeny of CTPs from trabecular surface cells may go on to fully express all three markers at high levels after a longer period of expansion.…”

Stroke Therapy: the Potential of Amniotic Fluid-Derived Stem Cells

“…Other recent studies have shown immunomodulatory properties of AFMSCs, which can inhibit the proliferation of T lymphocytes [8]. In another study, cultured AFSCs demonstrated an increase in CD105+ cells in the late-passage compared with the early-passage AFSC cultures [9]. Because CD105 is a mesenchymal marker and the long-term culture conditions allowed mesenchymal cell growth, AFSCs have been suggested to be mesenchymal precursors [9].…”

“…In another study, cultured AFSCs demonstrated an increase in CD105+ cells in the late-passage compared with the early-passage AFSC cultures [9]. Because CD105 is a mesenchymal marker and the long-term culture conditions allowed mesenchymal cell growth, AFSCs have been suggested to be mesenchymal precursors [9]. Recent in vitro analysis has found that AFSCs modulate lymphocyte proliferation in different manners according to gestational age (i.e., those derived from first-, second- or third-trimester) [10].…”